<![CDATA[Sur180 Therapeutics]]>https://www.sur180therapeutics.com/blogRSS for NodeWed, 04 Nov 2026 00:24:03 GMT<![CDATA[Endometriosis: The $220 Billion Market Opportunity]]>https://www.sur180therapeutics.com/post/endometriosis-the-220-billion-market-opportunity6aea424245f0aaa1eb836cc5Tue, 03 Nov 2026 21:53:33 GMTfabiolamplaza<![CDATA[Sur180 Therapeutics Research Featured in Public Health PR]]>https://www.sur180therapeutics.com/post/sur180-non-hormonal-endometriosis-crhr1-biology-of-reproduction6aea68ade6cd3b837a216b11Mon, 25 May 2026 04:00:00 GMTfabiolamplaza<![CDATA[Sur180 Therapeutics Featured on Notiséis WIPR]]>https://www.sur180therapeutics.com/post/sur180-notiseis-wipr-endometriosis6aea5f1745f0aaa1eb83ad7fFri, 27 Mar 2026 04:00:00 GMTfabiolamplaza<![CDATA[Sur180 Therapeutics at the SRI Annual Scientific Meeting]]>https://www.sur180therapeutics.com/post/sur180-sri-annual-scientific-meeting-20266aea63c3e6cd3b837a215d92Tue, 24 Mar 2026 04:00:00 GMTfabiolamplaza<![CDATA[Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis]]>https://www.sur180therapeutics.com/post/sur180-therapeutics-and-nura-health6aea5b47e6cd3b837a214a11Tue, 17 Mar 2026 22:23:07 GMTfabiolamplaza